Tyloxapol: Difference between revisions
Content deleted Content added
consistent citation formatting |
Citation bot (talk | contribs) m Alter: work. | You can use this bot yourself. Report bugs here. | Activated by User:Grimes2 | via #UCB_webform |
||
| Line 49: | Line 49: | ||
}} |
}} |
||
'''Tyloxapol''' is a nonionic liquid [[polymer]] of the alkyl aryl polyether alcohol type. It is used as a [[surfactant]] to aid [[liquefaction]] and removal of mucopurulent{{citation needed|date=December 2013}} (containing [[mucus]] and [[pus]]) bronchopulmonary secretions,<ref>{{cite journal | vauthors = Sehgal SS, Ewing CK, Richards T, Taeusch HW | title = Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study | journal = Journal of the National Medical Association | volume = 86 | issue = 1 | pages = 46–52 | date = January 1994 | pmid = 8151722 | pmc = 2607653 }}</ref><ref>{{cite journal | vauthors = Rubin BK, Ramirez O, King M | title = Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy | journal = Chest | volume = 101 | issue = 4 | pages = 1080–5 | date = April 1992 | pmid = 1555424 | doi = 10.1378/chest.101.4.1080 }}</ref> administered by inhalation through a [[nebulizer]]<ref>{{cite web | work = Drugs.com |
'''Tyloxapol''' is a nonionic liquid [[polymer]] of the alkyl aryl polyether alcohol type. It is used as a [[surfactant]] to aid [[liquefaction]] and removal of mucopurulent{{citation needed|date=December 2013}} (containing [[mucus]] and [[pus]]) bronchopulmonary secretions,<ref>{{cite journal | vauthors = Sehgal SS, Ewing CK, Richards T, Taeusch HW | title = Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study | journal = Journal of the National Medical Association | volume = 86 | issue = 1 | pages = 46–52 | date = January 1994 | pmid = 8151722 | pmc = 2607653 }}</ref><ref>{{cite journal | vauthors = Rubin BK, Ramirez O, King M | title = Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy | journal = Chest | volume = 101 | issue = 4 | pages = 1080–5 | date = April 1992 | pmid = 1555424 | doi = 10.1378/chest.101.4.1080 }}</ref> administered by inhalation through a [[nebulizer]]<ref>{{cite web | work = Drugs.com | url = https://www.drugs.com/dict/tyloxapol.html | title = Tyloxapol definition }}</ref> or with a stream of oxygen. |
||
With [[intraperitoneal injection]], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of [[triglyceride]]-rich [[lipoprotein]]s. This mechanism is used to induce experimental [[hyperlipidemia]] in animals.<ref>{{cite journal | vauthors = Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN | title = Experimental hyperlipidemia and the effect of NSAIDs | journal = Experimental and Molecular Pathology | volume = 73 | issue = 2 | pages = 135–8 | date = October 2002 | pmid = 12231215 | doi = 10.1006/exmp.2002.2449 }}</ref> |
With [[intraperitoneal injection]], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of [[triglyceride]]-rich [[lipoprotein]]s. This mechanism is used to induce experimental [[hyperlipidemia]] in animals.<ref>{{cite journal | vauthors = Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN | title = Experimental hyperlipidemia and the effect of NSAIDs | journal = Experimental and Molecular Pathology | volume = 73 | issue = 2 | pages = 135–8 | date = October 2002 | pmid = 12231215 | doi = 10.1006/exmp.2002.2449 }}</ref> |
||
Revision as of 05:32, 1 March 2020
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.209.660 |
| Chemical and physical data | |
| Formula | (C15H21O(C2H4O)m)n |
| Molar mass | variable |
  (what is this?) (verify) | |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are Exosurf and Alevaire.
References
- ^ Sehgal SS, Ewing CK, Richards T, Taeusch HW (January 1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
- ^ Rubin BK, Ramirez O, King M (April 1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–5. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ^ "Tyloxapol definition". Drugs.com.
- ^ Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN (October 2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology. 73 (2): 135–8. doi:10.1006/exmp.2002.2449. PMID 12231215.
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |